While TET2- (with controversial results) and DDX41-mutants seem to have a higher rate of HMA response, MDS patients harboring ASXL1 and specific DNMT3A variants (e.g., R882H) tend to have dismal outcomes (Fig. 3) [88–90]. The gene discussed is DDX41; the disease is myelodysplastic syndrome.